Literature DB >> 26473392

Distinct clinical and pathological phenotypes in frontotemporal dementia associated with MAPT, PGRN and C9orf72 mutations.

Julie S Snowden1,2, Jennifer Adams1,2, Jennifer Harris1,2, Jennifer C Thompson1,2, Sara Rollinson2, Anna Richardson1,2, Matthew Jones1,2, David Neary1, David M Mann2, Stuart Pickering-Brown2.   

Abstract

Our objective was to compare the clinical and pathological characteristics of frontotemporal dementia patients with MAPT, GRN and C9orf72 gene mutations. We carried out a cross-sectional comparative study of 74 gene-positive patients (15 MAPT, 17 GRN and 42 C9orf72). Thirty had post mortem pathological data permitting clinico-pathological correlation. MAPT patients were younger than other groups, and showed more frequent behavioural disinhibition, repetitive and stereotyped behaviours, semantic impairment and temporal predominance of atrophy. GRN patients were older at death and more likely to present with non-fluent aphasia. C9orf72 patients alone showed a co-occurrence of ALS. They showed more psychotic symptoms and irrational behaviour, yet were more often reported clinically as socially appropriate and warm. They showed less dietary change than other groups. C9orf72 patients with and without ALS differed only in frequency of psychosis. Greater clinical overlap was observed between GRN and C9orf72 compared to MAPT cases. MAPT cases had tau and GRN and C9orf72, with one exception, TDP-43 pathology. Non-fluent aphasia was linked to TDP subtype A in both GRN and C9orf72 cases and ALS with subtype B. In conclusion, the findings reinforce clinical heterogeneity in FTD and strengthen evidence that genotype influences clinical presentation. Clinical features may inform targeted genetic testing.

Entities:  

Keywords:  Frontotemporal dementia; behaviour; clinical phenotype; gene mutation; neuropathology

Mesh:

Substances:

Year:  2015        PMID: 26473392     DOI: 10.3109/21678421.2015.1074700

Source DB:  PubMed          Journal:  Amyotroph Lateral Scler Frontotemporal Degener        ISSN: 2167-8421            Impact factor:   4.092


  27 in total

Review 1.  From animal models to human disease: a genetic approach for personalized medicine in ALS.

Authors:  Vincent Picher-Martel; Paul N Valdmanis; Peter V Gould; Jean-Pierre Julien; Nicolas Dupré
Journal:  Acta Neuropathol Commun       Date:  2016-07-11       Impact factor: 7.801

Review 2.  Links Between the C9orf72 Repeat Expansion and Psychiatric Symptoms.

Authors:  Hannah E Silverman; Jill S Goldman; Edward D Huey
Journal:  Curr Neurol Neurosci Rep       Date:  2019-11-26       Impact factor: 5.081

Review 3.  Neuroimaging in Dementia.

Authors:  Adam M Staffaroni; Fanny M Elahi; Dana McDermott; Kacey Marton; Elissaios Karageorgiou; Simone Sacco; Matteo Paoletti; Eduardo Caverzasi; Christopher P Hess; Howard J Rosen; Michael D Geschwind
Journal:  Semin Neurol       Date:  2017-12-05       Impact factor: 3.420

4.  Multiple variants in families with amyotrophic lateral sclerosis and frontotemporal dementia related to C9orf72 repeat expansion: further observations on their oligogenic nature.

Authors:  Maria Pia Giannoccaro; Anna Bartoletti-Stella; Silvia Piras; Annalisa Pession; Patrizia De Massis; Federico Oppi; Michelangelo Stanzani-Maserati; Elena Pasini; Simone Baiardi; Patrizia Avoni; Piero Parchi; Rocco Liguori; Sabina Capellari
Journal:  J Neurol       Date:  2017-06-15       Impact factor: 4.849

Review 5.  A clinicopathological approach to the diagnosis of dementia.

Authors:  Fanny M Elahi; Bruce L Miller
Journal:  Nat Rev Neurol       Date:  2017-07-14       Impact factor: 42.937

Review 6.  Frontotemporal Dementia.

Authors:  Nicholas T Olney; Salvatore Spina; Bruce L Miller
Journal:  Neurol Clin       Date:  2017-05       Impact factor: 3.806

Review 7.  Frontotemporal dementia: latest evidence and clinical implications.

Authors:  Juan Joseph Young; Mallika Lavakumar; Deena Tampi; Silpa Balachandran; Rajesh R Tampi
Journal:  Ther Adv Psychopharmacol       Date:  2017-11-10

8.  Neurobehavioral Characteristics of FDG-PET Defined Right-Dominant Semantic Dementia: A Longitudinal Study.

Authors:  Alexis X Curet Burleson; Nha Trang Thu Pham; Marina Buciuc; Hugo Botha; Joseph R Duffy; Heather M Clark; Rene L Utianski; Mary M Machulda; Matthew C Baker; Rosa Rademakers; Val J Lowe; Jennifer L Whitwell; Keith A Josephs
Journal:  Dement Geriatr Cogn Disord       Date:  2021-03-23       Impact factor: 2.959

9.  Early symptoms in symptomatic and preclinical genetic frontotemporal lobar degeneration.

Authors:  Tamara Paulo Tavares; Derek G V Mitchell; Kristy Kl Coleman; Brenda L Coleman; Christen L Shoesmith; Christopher R Butler; Isabel Santana; Adrian Danek; Alexander Gerhard; Alexandre de Mendonca; Barbara Borroni; Maria Carmela Tartaglia; Caroline Graff; Daniela Galimberti; Fabrizio Tagliavini; Fermin Moreno; Giovanni Frisoni; James Benedict Rowe; Johannes Levin; John Cornelis Van Swieten; Markus Otto; Matthis Synofzik; Raquel Sanchez-Valle; Rik Vandenberghe; Robert Jr Laforce; Roberta Ghidoni; Sandro Sorbi; Simon Ducharme; Mario Masellis; Jonathan Rohrer; Elizabeth Finger
Journal:  J Neurol Neurosurg Psychiatry       Date:  2020-08-07       Impact factor: 10.154

10.  Apathy in presymptomatic genetic frontotemporal dementia predicts cognitive decline and is driven by structural brain changes.

Authors:  Maura Malpetti; P Simon Jones; Kamen A Tsvetanov; Timothy Rittman; John C van Swieten; Barbara Borroni; Raquel Sanchez-Valle; Fermin Moreno; Robert Laforce; Caroline Graff; Matthis Synofzik; Daniela Galimberti; Mario Masellis; Maria Carmela Tartaglia; Elizabeth Finger; Rik Vandenberghe; Alexandre de Mendonça; Fabrizio Tagliavini; Isabel Santana; Simon Ducharme; Chris R Butler; Alexander Gerhard; Johannes Levin; Adrian Danek; Markus Otto; Giovanni B Frisoni; Roberta Ghidoni; Sandro Sorbi; Carolin Heller; Emily G Todd; Martina Bocchetta; David M Cash; Rhian S Convery; Georgia Peakman; Katrina M Moore; Jonathan D Rohrer; Rogier A Kievit; James B Rowe
Journal:  Alzheimers Dement       Date:  2020-12-14       Impact factor: 16.655

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.